-
Mashup Score: 1Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni - 9 month(s) ago
In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Extended follow-up results of #CheckMate274 and results of pembrolizumab monotherapy in BCG-unresponsive HR #NMIBC: findings from cohort B of #KEYNOTE057. Join Michiel Van der Heijden, PhD @NKI_nl and @CaPsurvivorship @DanaFarber on UroToday > https://t.co/8FY6IuKpKh https://t.co/lhNd6RPe1g
-
-
Mashup Score: 0
Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA https://t.co/mo0bovgJpH
-
-
Mashup Score: 1Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni - 11 month(s) ago
In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD https://t.co/cd75fjpK4t
-
-
Mashup Score: 0
Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Extended follow-up results of #CheckMate274 and results of pembrolizumab monotherapy in BCG-unresponsive HR #NMIBC: findings from cohort B of #KEYNOTE057. Join Michiel Van der Heijden, PhD @NKI_nl and @CaPsurvivorship @DanaFarber on UroToday > https://t.co/8FY6IuKpKh https://t.co/Oq47Zd9f2i
-
-
Mashup Score: 0
Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA https://t.co/RtOFbRpKo6
-
-
Mashup Score: 2Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni - 12 month(s) ago
In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD https://t.co/N0cb9iEO0v
-
-
Mashup Score: 7
AUA 2023, KEYNOTE-057 study, Bacillus Calmette-Guerin (BCG), BCG treatment, Pembrolizumab, high risk non-muscle invasive bladder cancer (HR NMIBC), bladder cancer quality of life.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab for patients with high-risk #NMIBC unresponsive to BCG: Efficacy and evaluation of subsequent cystectomy from Cohort B of phase 2 #KEYNOTE057 study. Presented by @eric_facs @OSU_Urology. #AUA23 coverage by @RuchikaTalwarMD > https://t.co/sXZTZyHJfX #BladderCancer https://t.co/f3vZ3AUlzK
-
-
Mashup Score: 0
Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Results from cohort B of the phase 2 #KEYNOTE057 trial, pembrolizumab monotherapy for patients with high-risk #NMIBC unresponsive to BCG. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/aN8kZqw7BA https://t.co/TLuoB2W0N1
-
-
Mashup Score: 2
Michiel Van der Heijden discusses two abstracts on the use of immunotherapy in bladder cancer during his discussion with Alicia Morgans. The first abstract looked at the use of pembrolizumab in patients with non-muscle invasive bladder cancer, specifically those with high-grade TA or T1 disease that is refractory to BCG treatment. The study showed a 43% recurrence-free survival rate at one…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Extended follow-up results of #CheckMate274 and results of pembrolizumab monotherapy in BCG-unresponsive HR #NMIBC: findings from cohort B of #KEYNOTE057. Join Michiel Van der Heijden, PhD @NKI_nl and @CaPsurvivorship @DanaFarber on UroToday > https://t.co/8FY6IuKpKh https://t.co/ZiLAGSXLZC
-
Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD https://t.co/uXbYvcQuol